---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-039757"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2023-02-15T23:59:59+00:00"
generated_at: "2026-06-19T11:11:34.362212+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Karyopharm FY2022 total revenue $157.1M, net loss $165.3M; FY2023 guidance $160-175M

## Summary
- U.S. XPOVIO net product revenue $120.4M in FY2022, up 22% YoY from $98.4M.
- FY2022 net loss $165.3M ($2.02/share) vs net loss $124.1M ($1.65/share) in 2021.
- Cash, cash equivalents and investments $279.7M at Dec 31, 2022; $165M private placement extends cash runway into late 2025.
- FY2023 guidance: total revenue $160-175M, XPOVIO net product revenue $125-140M, non-GAAP R&D+SG&A $260-280M.
- Initiated Phase 3 selinexor maintenance in TP53 wild-type endometrial cancer; Phase 1 MF and Phase 2 MDS data due 1H 2023.

## SEC filing metadata
- accession: 0001193125-23-039757
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2023-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312523039757/0001193125-23-039757-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312523039757/d374435d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-039757
- JSON: https://secwatch.observer/filing/0001193125-23-039757.json
- Plain text: https://secwatch.observer/filing/0001193125-23-039757.txt

## Key facts
- Earnings Releases
  Karyopharm Therapeutics Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue Total revenue for the fourth quarter of 2022 was $33.6 million, compared to $126.3 million for the fourth quarter of 202. Guidance initiated.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Revenue: Total revenue for the fourth quarter of 2022 was $33.6 million, compared to $126.3 million for the fourth quarter of 202
  - Guidance: initiated
  - Result: reported results
  source text: On February 15, 2023, Karyopharm Therapeutics Inc. announced its financial results for the fourth quarter and full year ended December 31, 2022 and will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312523039757/0001193125-23-039757-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.